However, adherence is a concern for patients with FGF23‐related hypophosphatemic rickets/osteomalacia who require long‐term treatment, as the drug requires subcutaneous injection once a month in adults and twice a month in children. This evidence concerns the gene FGF23 and hypophosphatemic rickets.